Crown Bioscience

About Crown Bioscience

Crown Bioscience operates as a global contract research organization (CRO), functioning as a key partner for pharmaceutical and biotechnology firms engaged in drug discovery and development. Founded in 2006 with its headquarters established in San Diego, California, the company has expanded its footprint to include 11 facilities across the United States, Europe, and the Asia-Pacific region. The firm's business model is centered on providing preclinical and translational research services, which allows clients to assess the effectiveness and pharmacological characteristics of drug candidates before they advance to clinical trials.

The company's history is marked by significant strategic growth and expansion. Shortly after its founding, Crown Bioscience established an oncology platform in 2007, followed by research and development centers in China (2008) and the U.S. (2009). A series of acquisitions has been central to its expansion, including the purchase of PRECOS Limited in 2013, which enhanced its bioluminescence imaging capabilities, and Molecular Response in 2015, which broadened its patient-derived xenograft (PDX) and tumor biobank models. A pivotal moment occurred in January 2018 when Crown Bioscience was acquired by JSR Corporation for approximately $400 million, integrating it into JSR's Life Sciences division. This acquisition was JSR's largest life sciences investment at the time, aimed at extending its portfolio into contract research and development. Post-acquisition, Crown Bioscience has continued its growth trajectory, acquiring OcellO B.V. in 2021 to expand its in vitro services and the IndivuServ business unit from Indivumed GmbH in 2023 to bolster its biobank and translational research platforms.

Crown Bioscience offers an integrated suite of solutions utilizing in vivo, in vitro, ex vivo, and in silico models. A core component of its offering is the world's largest commercial collection of PDX models, which are instrumental in reflecting the complexity of human tumors for research purposes. The company also provides over 600 tumor organoid models developed with Hubrecht Organoid Technology, spanning 22 cancer indications. For its clients in the pharmaceutical and biotech industries, these platforms provide predictive data that helps to de-risk and accelerate the drug development timeline. The company also maintains a substantial biobank of liquid and human biospecimens that are annotated with comprehensive clinical data, further supporting biomarker discovery and personalized medicine research.